220 related articles for article (PubMed ID: 28291643)
1. Successful treatment of pituitary carcinoma with concurrent radiation, temozolomide, and bevacizumab after resection.
Touma W; Hoostal S; Peterson RA; Wiernik A; SantaCruz KS; Lou E
J Clin Neurosci; 2017 Jul; 41():75-77. PubMed ID: 28291643
[TBL] [Abstract][Full Text] [Related]
2. Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016.
McCormack A; Dekkers OM; Petersenn S; Popovic V; Trouillas J; Raverot G; Burman P;
Eur J Endocrinol; 2018 Mar; 178(3):265-276. PubMed ID: 29330228
[TBL] [Abstract][Full Text] [Related]
3. Radiotherapy with concurrent temozolomide for the management of extraneural metastases in pituitary carcinoma.
Kamiya-Matsuoka C; Cachia D; Waguespack SG; Crane CH; Mahajan A; Brown PD; Nam JY; McCutcheon IE; Penas-Prado M
Pituitary; 2016 Aug; 19(4):415-21. PubMed ID: 27106209
[TBL] [Abstract][Full Text] [Related]
4. Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas.
Lasolle H; Cortet C; Castinetti F; Cloix L; Caron P; Delemer B; Desailloud R; Jublanc C; Lebrun-Frenay C; Sadoul JL; Taillandier L; Batisse-Lignier M; Bonnet F; Bourcigaux N; Bresson D; Chabre O; Chanson P; Garcia C; Haissaguerre M; Reznik Y; Borot S; Villa C; Vasiljevic A; Gaillard S; Jouanneau E; Assié G; Raverot G
Eur J Endocrinol; 2017 Jun; 176(6):769-777. PubMed ID: 28432119
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide.
Bengtsson D; Schrøder HD; Andersen M; Maiter D; Berinder K; Feldt Rasmussen U; Rasmussen ÅK; Johannsson G; Hoybye C; van der Lely AJ; Petersson M; Ragnarsson O; Burman P
J Clin Endocrinol Metab; 2015 Apr; 100(4):1689-98. PubMed ID: 25646794
[TBL] [Abstract][Full Text] [Related]
6. Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing's disease--report of a case and literature review.
Curtò L; Torre ML; Ferraù F; Pitini V; Altavilla G; Granata F; Longo M; Hofland LJ; Trimarchi F; Cannavò S
ScientificWorldJournal; 2010 Nov; 10():2132-8. PubMed ID: 21057727
[TBL] [Abstract][Full Text] [Related]
7. Treatment of pituitary carcinomas and atypical pituitary adenomas: a review.
Hirohata T; Ishii Y; Matsuno A
Neurol Med Chir (Tokyo); 2014; 54(12):966-73. PubMed ID: 25446382
[TBL] [Abstract][Full Text] [Related]
8. Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature.
Annamalai AK; Dean AF; Kandasamy N; Kovacs K; Burton H; Halsall DJ; Shaw AS; Antoun NM; Cheow HK; Kirollos RW; Pickard JD; Simpson HL; Jefferies SJ; Burnet NG; Gurnell M
Pituitary; 2012 Sep; 15(3):276-87. PubMed ID: 22076588
[TBL] [Abstract][Full Text] [Related]
9. Temozolomide therapy for aggressive pituitary Crooke's cell corticotropinoma causing Cushing's Disease - a case report with literature review.
Gilis-Januszewska A; Wilusz M; Pantofliński J; Turek-Jabrocka R; Sokołowski G; Sowa-Staszczak A; Kluczyński Ł; Pach D; Zieliński G; Hubalewska-Dydejczyk A
Endokrynol Pol; 2018; 69(3):306-312. PubMed ID: 29319131
[TBL] [Abstract][Full Text] [Related]
10. DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors.
Hirohata T; Asano K; Ogawa Y; Takano S; Amano K; Isozaki O; Iwai Y; Sakata K; Fukuhara N; Nishioka H; Yamada S; Fujio S; Arita K; Takano K; Tominaga A; Hizuka N; Ikeda H; Osamura RY; Tahara S; Ishii Y; Kawamata T; Shimatsu A; Teramoto A; Matsuno A
J Clin Endocrinol Metab; 2013 Mar; 98(3):1130-6. PubMed ID: 23365123
[TBL] [Abstract][Full Text] [Related]
11. Temozolomide for corticotroph pituitary adenomas refractory to standard therapy.
Dillard TH; Gultekin SH; Delashaw JB; Yedinak CG; Neuwelt EA; Fleseriu M
Pituitary; 2011 Mar; 14(1):80-91. PubMed ID: 20972839
[TBL] [Abstract][Full Text] [Related]
12. A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report.
Murakami M; Mizutani A; Asano S; Katakami H; Ozawa Y; Yamazaki K; Ishida Y; Takano K; Okinaga H; Matsuno A
Neurosurgery; 2011 Jun; 68(6):E1761-7; discussion E1767. PubMed ID: 21389894
[TBL] [Abstract][Full Text] [Related]
13. Aggressive silent corticotroph adenoma progressing to pituitary carcinoma: the role of temozolomide therapy.
Moshkin O; Syro LV; Scheithauer BW; Ortiz LD; Fadul CE; Uribe H; Gonzalez R; Cusimano M; Horvath E; Rotondo F; Kovacs K
Hormones (Athens); 2011; 10(2):162-7. PubMed ID: 21724542
[TBL] [Abstract][Full Text] [Related]
14. Temozolomide for aggressive ACTH pituitary tumors: failure of a second course of treatment.
Campderá M; Palacios N; Aller J; Magallón R; Martín P; Saucedo G; Lilienfeld H; Estrada J
Pituitary; 2016 Apr; 19(2):158-66. PubMed ID: 26586560
[TBL] [Abstract][Full Text] [Related]
15. Pituitary atypical adenoma or carcinoma sensitive to temozolomide combined with radiation therapy: a case report of early identification and management.
Zhong C; Yin S; Zhou P; Jiang S
Turk Neurosurg; 2014; 24(6):963-6. PubMed ID: 25448217
[TBL] [Abstract][Full Text] [Related]
16. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.
Raverot G; Sturm N; de Fraipont F; Muller M; Salenave S; Caron P; Chabre O; Chanson P; Cortet-Rudelli C; Assaker R; Dufour H; Gaillard S; François P; Jouanneau E; Passagia JG; Bernier M; Cornélius A; Figarella-Branger D; Trouillas J; Borson-Chazot F; Brue T
J Clin Endocrinol Metab; 2010 Oct; 95(10):4592-9. PubMed ID: 20660056
[TBL] [Abstract][Full Text] [Related]
17. Early Recognition and Initiation of Temozolomide Chemotherapy for Refractory, Invasive Pituitary Macroprolactinoma with Long-Term Sustained Remission.
Barkhoudarian G; Palejwala SK; Ogunbameru R; Wei H; Eisenberg A; Kelly DF
World Neurosurg; 2018 Oct; 118():118-124. PubMed ID: 30031177
[TBL] [Abstract][Full Text] [Related]
18. Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center.
Ceccato F; Lombardi G; Manara R; Emanuelli E; Denaro L; Milanese L; Gardiman MP; Bertorelle R; Scanarini M; D'Avella D; Occhi G; Boscaro M; Zagonel V; Scaroni C
J Neurooncol; 2015 Mar; 122(1):189-96. PubMed ID: 25555563
[TBL] [Abstract][Full Text] [Related]
19. Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy.
Hagen C; Schroeder HD; Hansen S; Hagen C; Andersen M
Eur J Endocrinol; 2009 Oct; 161(4):631-7. PubMed ID: 19654234
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial.
Balana C; De Las Penas R; Sepúlveda JM; Gil-Gil MJ; Luque R; Gallego O; Carrato C; Sanz C; Reynes G; Herrero A; Ramirez JL; Pérez-Segura P; Berrocal A; Vieitez JM; Garcia A; Vazquez-Estevez S; Peralta S; Fernandez I; Henriquez I; Martinez-Garcia M; De la Cruz JJ; Capellades J; Giner P; Villà S
J Neurooncol; 2016 May; 127(3):569-79. PubMed ID: 26847813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
